Question 1

What is a liquid biopsy and how is it different from a traditional biopsy?

Accepted Answer

A traditional biopsy involves surgically removing a small piece of tissue from the body to test it for cancer — which can be uncomfortable and invasive. A liquid biopsy, by contrast, uses a simple blood draw to detect traces of cancer-related genetic material circulating in the bloodstream. It is far less invasive, quicker, and can potentially screen for multiple cancer types at once, which is what makes tests like GRAIL's Galleri so exciting.

Question 2

What is GRAIL's Galleri test and why does the FDA review matter?

Accepted Answer

The Galleri test is a pioneering multi-cancer early detection blood test developed by GRAIL. It analyses DNA shed by cancer cells into the blood and can identify signals associated with over 50 different cancer types from a single blood draw. The FDA (the US Food and Drug Administration) is the body that decides whether new medical tests and devices are safe and effective enough to be used widely. Its advisory panel is scheduled to review Galleri's approval application in September 2026, and a positive outcome could open the door for the test to become a mainstream screening tool — transforming preventative healthcare.

Question 3

What does 'premarket approval' mean when it comes to medical tests?

Accepted Answer

Before a new medical device or diagnostic test can be sold and used in the United States, it typically needs to go through a rigorous review process by the FDA. Premarket approval (PMA) is the strictest type of review, reserved for high-risk or novel technologies. It means the company must prove with strong clinical evidence that its product is both safe and effective. For GRAIL's Galleri test, receiving PMA would effectively confirm that it meets the gold standard for use in clinical settings.

Question 4

What is next-generation sequencing (NGS) and why is it relevant here?

Accepted Answer

Next-generation sequencing (NGS) is a powerful technology that can rapidly read and analyse vast amounts of genetic information from a biological sample. In the context of cancer diagnostics, NGS is used to identify specific mutations or genetic signals that indicate the presence of cancer. Many of the companies in this group — including Illumina and Pacific Biosciences — develop the NGS hardware and tools that make liquid biopsy tests possible. Without NGS, these types of advanced blood tests simply could not exist.

Question 5

What does 'analyst rating' mean and why should I pay attention to it?

Accepted Answer

An analyst rating is an opinion issued by a financial professional — typically working at a bank or investment firm — about whether a stock is worth buying, holding, or selling. Ratings are usually expressed as 'Buy', 'Hold', or 'Sell' (or similar terms). These ratings are based on detailed research into a company's financials, industry trends, and future prospects. While they are not guarantees, they can be a useful guide for understanding how experts view a company's potential.

Question 6

What does 'projected sales' mean for these companies?

Accepted Answer

Projected sales — sometimes called revenue forecasts — represent analysts' best estimates of how much money a company is expected to earn from its products and services over a coming period, typically the next 12 months. For companies in fast-growing sectors like cancer diagnostics, rising projected sales can signal strong demand and a growing market. It is one of the key data points used to assess whether a company is on a healthy growth trajectory.

Question 7

Is investing in this type of theme higher risk than investing in more established sectors?

Accepted Answer

Generally speaking, yes. Companies in emerging areas like liquid biopsy and genomic diagnostics are often in earlier stages of commercialisation, meaning their revenues may still be growing or their products may still be seeking regulatory approval. This can mean higher potential rewards if things go well, but also greater uncertainty if regulatory decisions are delayed or unfavourable. That said, this group also includes larger, more established life sciences companies — such as Thermo Fisher Scientific, Roche, and Danaher — which may offer a degree of stability alongside the growth-focused names.

Top Picks from This Group

Why You'll Want to Watch These Stocks

A Single Blood Test That Could Change Everything

Experts Are Already Paying Close Attention

A Market on the Verge of Taking Off

바스켓의 재무 규모

12 Month Growth Potential

About This Group of Stocks

Our Expert Thinking

What You Need to Know

Why These Stocks

Group Performance Snapshot

12개월 평균 수익

애널리스트 매수 의견 종목

Why Invest with Nemo Money?

Zero Commission

Trusted & Regulated

Discover More Opportunities

HIV Therapeutics (Once-Daily Pill) Reshapes Market

Media Giants vs FCC | Regulatory Risk Exposed

Invest in AI Memory Stocks (HBM & Equipment Leaders)

Frequently Asked Questions

Cancer Diagnostics Stocks | Liquid Biopsy Catalyst